Wells Fargo’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-135,195
| Closed | -$5.09M | – | 7899 |
|
|
2021
Q1 | $5.09M | Sell |
135,195
-339,659
| -72% | -$8.47M | ﹤0.01% | 2830 |
|
|
2020
Q4 | $8.08M | Buy |
474,854
+304,557
| +179% | +$3.82M | ﹤0.01% | 2291 |
|
|
2020
Q3 | $801K | Buy |
170,297
+125,213
| +278% | +$636K | ﹤0.01% | 4023 |
|
|
2020
Q2 | $275K | Buy |
45,084
+11,827
| +36% | +$48.7K | ﹤0.01% | 4718 |
|
|
2020
Q1 | $76K | Buy |
33,257
+4,685
| +16% | +$19.9K | ﹤0.01% | 5196 |
|
|
2019
Q4 | $131K | Sell |
28,572
-43,210
| -60% | -$171K | ﹤0.01% | 5177 |
|
|
2019
Q3 | $278K | Sell |
71,782
-7,453
| -9% | -$40.9K | ﹤0.01% | 4764 |
|
|
2019
Q2 | $478K | Sell |
79,235
-17,673
| -18% | -$169K | ﹤0.01% | 4412 |
|
|
2019
Q1 | $1.3M | Buy |
96,908
+3,532
| +4% | +$40.3K | ﹤0.01% | 3697 |
|
|
2018
Q4 | $868K | Sell |
93,376
-134,978
| -59% | -$1.61M | ﹤0.01% | 3947 |
|
|
2018
Q3 | $3.18M | Sell |
228,354
-12,792
| -5% | -$190K | ﹤0.01% | 3019 |
|
|
2018
Q2 | $3.81M | Buy |
241,146
+4,781
| +2% | +$83.4K | ﹤0.01% | 2934 |
|
|
2018
Q1 | $4.06M | Buy |
236,365
+49,068
| +26% | +$957K | ﹤0.01% | 2806 |
|
|
2017
Q4 | $4.11M | Buy |
187,297
+1,915
| +1% | +$61.6K | ﹤0.01% | 2757 |
|
|
2017
Q3 | $7.58M | Buy |
185,382
+7,294
| +4% | +$229K | ﹤0.01% | 2186 |
|
|
2017
Q2 | $5.36M | Sell |
178,088
-7,178
| -4% | -$224K | ﹤0.01% | 2385 |
|
|
2017
Q1 | $6.7M | Buy |
185,266
+29,701
| +19% | +$1.31M | ﹤0.01% | 2199 |
|
|
2016
Q4 | $7.79M | Sell |
155,565
-1,980
| -1% | -$104K | ﹤0.01% | 2047 |
|
|
2016
Q3 | $8.27M | Buy |
157,545
+11,111
| +8% | +$531K | ﹤0.01% | 1888 |
|
|
2016
Q2 | $6.05M | Sell |
146,434
-111
| -0.1% | -$4.83K | ﹤0.01% | 2179 |
|
|
2016
Q1 | $5.95M | Buy |
146,545
+30,057
| +26% | +$1.03M | ﹤0.01% | 2180 |
|
|
2015
Q4 | $4.83M | Sell |
116,488
-2,179
| -2% | -$73K | ﹤0.01% | 2353 |
|
|
2015
Q3 | $1.83M | Sell |
118,667
-31,183
| -21% | -$670K | ﹤0.01% | 3067 |
|
|
2015
Q2 | $3.72M | Buy |
149,850
+42,007
| +39% | +$936K | ﹤0.01% | 2633 |
|
|
2015
Q1 | $2.46M | Sell |
107,843
-22,612
| -17% | -$571K | ﹤0.01% | 2889 |
|
|
2014
Q4 | $3.52M | Sell |
130,455
-24,357
| -16% | -$419K | ﹤0.01% | 2597 |
|
|
2014
Q3 | $1.82M | Buy |
154,812
+3,079
| +2% | +$38.8K | ﹤0.01% | 3063 |
|
|
2014
Q2 | $2.36M | Sell |
151,733
-2,063
| -1% | -$29.6K | ﹤0.01% | 2902 |
|
|
2014
Q1 | $3.02M | Buy |
153,796
+108,539
| +240% | +$1.84M | ﹤0.01% | 2690 |
|
|
2013
Q4 | $760K | Buy |
+45,257
| New | +$562K | ﹤0.01% | 3581 |
|
Wells Fargo's FPRX Position: Q2 2021 in Review
Wells Fargo sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 135,195 shares — an estimated $5.09M sold.
Wells Fargo first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $8.27M in Q3 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Wells Fargo reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Wells Fargo sold 135,195 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $5.09M.
- Wells Fargo first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
- Wells Fargo's Five Prime Therapeutics, Inc. position peaked at $8.27M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Wells Fargo's 13F filing for Q2 2021, filed 16 Aug 2021.